<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104026">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675661</url>
  </required_header>
  <id_info>
    <org_study_id>CTN-0053</org_study_id>
    <nct_id>NCT01675661</nct_id>
  </id_info>
  <brief_title>Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment</brief_title>
  <acronym>ACCENT</acronym>
  <official_title>Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the impact of N-acetylcysteine (NAC) 1200
      mg versus matched placebo (PBO) twice daily, added to contingency management (CM), on
      cannabis use among treatment-seeking cannabis-dependent adults (ages 18-50).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The odds of negative urine cannabinoid tests during treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome is the abstinence rate over the 12 weeks of treatment.  Abstinence is based on a weekly urine drug screen confirmed by central laboratory testing and defined as a negative cannabinoid result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-of-treatment cannabis abstinence, measured by negative cannabinoid testing throughout the last two and last four weeks of treatment.</measure>
    <time_frame>Weeks 9-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Odds of negative weekly cannabinoid tests during the first 8 weeks of active treatment</measure>
    <time_frame>Weeks 1-8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two- and four-week abstinence, based on urine cannabinoid tests, anchored at week 8</measure>
    <time_frame>Weeks 5-8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two- and four-week end-of-treatment abstinence assessed via self-reported abstinence confirmed by negative urine cannabinoid tests</measure>
    <time_frame>Weeks 9-12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other cannabis-related measures (e.g., craving, withdrawal, compulsive use, cannabis-associated problems)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other substance use (e.g., cigarettes per day among tobacco smokers)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nicotine dependence among tobacco smokers</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome will also be tested among the subgroup of participants that meet criteria for medication compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of change in cannabis use on depressive symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of change in cannabis use on anxiety symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of change in cannabis use on sleep quality</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of change in cannabis use on quality of life</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between self-report (Timeline Follow-Back) and qualitative urine cannabinoid testing</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between self-report (Timeline Follow-Back) and quantitative urine cannabinoid testing</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between self-report (Timeline Follow Back) and quantitative urine cannabinoid testing dichotomized using methods described in Schwilke et al., 2011</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cannabis Dependence</condition>
  <arm_group>
    <arm_group_label>NAC plus CM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N-acetylcysteine (NAC) plus Contingency Management (CM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus CM</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus Contingency Management (CM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily.  All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.</description>
    <arm_group_label>NAC plus CM</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily.  All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.</description>
    <arm_group_label>Placebo plus CM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50 years

          -  Must be able to understand the study and provide written informed consent

          -  Must meet current DSM-IV criteria for cannabis dependence in the last 30 days

          -  Must express interest in treatment for cannabis dependence

          -  Must submit a positive urine cannabinoid test during screening

          -  Women of child bearing potential must agree to use appropriate birth control methods
             during study participation: oral contraceptives, contraceptive patch, barrier
             (diaphragm or condom), levonorgestrel implant, medroxyprogesterone acetate, complete
             abstinence from sexual intercourse, or hormonal contraceptive vaginal ring

        Exclusion Criteria:

          -  Allergy or intolerance to N-Acetylcysteine

          -  Women who are pregnant or lactating

          -  Current use of NAC or any supplement containing N-Acetylcysteine (must agree not to
             take any such supplement throughout study participation)

          -  Use of carbamazepine or nitroglycerin within 14 days of randomization

          -  Current enrollment in treatment for cannabis dependence

          -  Any use of synthetic cannabinoids (such as K2/Spice) in the 30 days prior to
             screening or during the period between screening and randomization

          -  Current substance dependence, other than cannabis or nicotine

          -  Urine drug screen positive for any drug of abuse other than cannabis or amphetamines
             at the randomization visit (Only participants who have a valid prescription for
             amphetamines (e.g., for ADHD) may be included)

          -  Urine drug screen positive for amphetamines at the randomization visit without having
             a valid prescription for it

          -  Maintenance treatment with buprenorphine or methadone

          -  Recent history of asthma (within the last 3 years)

          -  History of seizure disorder, bipolar disorder, schizophrenia, or other significant or
             unstable medical or psychiatric illness that may place the participant at increased
             risk in the judgment of the medical clinician

          -  Significant risk of homicide or suicide
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin M Gray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Integrated Substance Abuse Programs</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Hasson, MSW</last_name>
      <phone>310-267-5224</phone>
      <email>alhasson@ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Larissa Mooney, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APT Foundation, Inc.</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Dwy</last_name>
      <phone>203-285-1753</phone>
      <email>SDwy@aptfoundation.org</email>
    </contact>
    <investigator>
      <last_name>Kathleen Carroll, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanna Babalonis, Ph.D.</last_name>
      <phone>859-257-1881</phone>
      <email>babalonis@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Walsh, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CODA, Inc.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Asphaug, MScPH</last_name>
      <phone>971-202-7829</phone>
      <email>VictoriaAsphaug@codainc.org</email>
    </contact>
    <investigator>
      <last_name>Katharina Wiest, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Behavioral Health Services of Pickens County</name>
      <address>
        <city>Pickens</city>
        <state>South Carolina</state>
        <zip>29671</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Chapman, CAC II</last_name>
      <phone>864-898-2938</phone>
      <email>echapman@bhspickens.com</email>
    </contact>
    <investigator>
      <last_name>Aimee McRae-Clark, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Juarez</last_name>
      <phone>(210) 562-5435</phone>
      <email>juarezl@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Sharpe Potter, Ph.D., M.P.H.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 14, 2014</lastchanged_date>
  <firstreceived_date>August 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Kevin Gray</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
